awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q34788381-0D49566E-E6C6-4555-9035-BE362A23F368
Q34788381-0D49566E-E6C6-4555-9035-BE362A23F368
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34788381-0D49566E-E6C6-4555-9035-BE362A23F368
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
P2860
Q34788381-0D49566E-E6C6-4555-9035-BE362A23F368
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34788381-0D49566E-E6C6-4555-9035-BE362A23F368
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
be5785cf000da412af12f9d614db0992be06798d
P2860
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.